Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 39. Отображено 35.
29-06-2017 дата публикации

NMR QUANTIFICATION OF TMAO

Номер: US20170184521A1
Принадлежит: Liposcience Inc

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM.

Подробнее
10-01-2017 дата публикации

NMR quantification of TMAO

Номер: US0009541620B2

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM.

Подробнее
18-10-2016 дата публикации

NMR measurements of NMR biomarker GlycA

Номер: US0009470771B2

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Подробнее
05-01-2017 дата публикации

NMR Measurements of NMR Biomarker GlycA

Номер: US20170003269A1
Принадлежит: Liposcience Inc

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states . The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Подробнее
03-11-2016 дата публикации

Multi-Parameter Diabetes Risk Evaluations

Номер: US20160321424A1
Принадлежит:

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. 1. A method of evaluating a subject's risk of developing type 2 diabetes and/or of having prediabetes , comprising:programmatically calculating a diabetes risk index score of a subject using at least one defined mathematical model of risk of developing type 2 diabetes that includes at least one lipoprotein component, at least one branched chain amino acid and at least one inflammatory biomarker obtained from at least one in vitro biosample of the subject.2. The method of claim 1 , further comprising programmatically defining at least two different mathematical models of risk of developing type 2 diabetes claim 1 , the at least two different mathematical models including one for subjects on a statin therapy that includes lipoprotein component that are statin insensitive and one for subjects not on a statin therapy.3. The method of claim 1 , further comprising programmatically defining at least two different mathematical models of risk of developing type 2 diabetes claim 1 , the at least two different mathematical models with different lipoprotein components including one for fasting biosamples claim 1 , and one for non-fasting biosamples.45.-. (canceled)6. The method of claim 1 , wherein the at least one defined mathematical model of risk includes NMR derived measurements of a plurality of selected lipoprotein components of the at least one biosample of the subject claim 1 , and NMR measurements of at least one of GlycA and valine.78.-. (canceled)9. The method of claim 1 , wherein the defined mathematical risk model includes only NMR derived measurements of a ...

Подробнее
03-01-2017 дата публикации

NMR quantification of TMAO

Номер: US0009535144B2

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM.

Подробнее
17-10-2017 дата публикации

Multi-parameter diabetes risk evaluations

Номер: US0009792410B2
Принадлежит: LipoScience, Inc., LIPOSCIENCE INC

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Подробнее
05-12-2013 дата публикации

NMR QUANTIFICATION OF TMAO

Номер: US20130325353A1
Принадлежит:

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM. 1. A method of determining a measure of TMAO in in vitro biosamples , comprising:electronically determining a level of trimethylamine-N-oxide (“TMAO”) of an in vitro biosample using a defined TMAO peak region having a single TMAO peak residing between about 3.2 and 3.4 ppm of a proton NMR spectrum.2. The method of claim 1 , further comprising:electronically identifying a pH-stable reference peak region in the NMR spectrum of the biosample;electronically identifying a defined calibration peak region in the NMR spectrum of the biosample, wherein the calibration peak region has a location that changes based on pH of the biosample; andelectronically calculating a distance between the reference and calibration peak regions; thenelectronically determining a location of the TMAO peak for the defined TMAO peak region based on the calculated distance.3. The method of claim 2 , wherein the electronically determining the TMAO peak region location is carried out using a defined relationship of location of the reference peak region to location of the calibration peak region.4. The method of claim 1 , wherein the biosample is a blood plasma or serum wherein the defined TMAO peak is at about 3.30 ppm.5. The method of claim 1 , further comprising:electronically identifying a defined calibration peak multiplet with peaks that can vary in distance apart from one another based on pH of the biosample;determining at least one distance between one or more of the peaks in the calibration peak multiplet; andelectronically determining a pH of the biosample based on the at least one determined distance;wherein the ...

Подробнее
12-12-2013 дата публикации

Nmr measurements of glyca

Номер: US20130328561A1
Принадлежит: Liposcience Inc

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Подробнее
12-12-2013 дата публикации

MULTI-PARAMETER DIABETES RISK EVALUATIONS

Номер: US20130332082A1
Принадлежит:

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. 1. A method of evaluating a subject's risk of developing type 2 diabetes and/or of having prediabetes , comprising:programmatically calculating a diabetes risk index score of a subject using at least one defined mathematical model of risk of developing type 2 diabetes that includes at least one lipoprotein component, at least one branched chain amino acid and at least one inflammatory biomarker obtained from at least one in vitro biosample of the subject.2. The method of claim 1 , further comprising programmatically defining at least two different mathematical models of risk of developing type 2 diabetes claim 1 , the at least two different mathematical models including one for subjects on a statin therapy that includes lipoprotein component that are statin insensitive and one for subjects not on a statin therapy.3. The method of claim 1 , further comprising programmatically defining at least two different mathematical models of risk of developing type 2 diabetes claim 1 , the at least two different mathematical models with different lipoprotein components including one for fasting biosamples claim 1 , and one for non-fasting biosamples.4. The method of claim 1 , further comprising programmatically generating a report with a graph of risk of progression to type 2 diabetes in the future over a 1-7 year period versus ranges of fasting glucose levels and a quartile of risk associated with the diabetes risk index score.5. The method of claim 1 , wherein the graph shows references of at least first (low) and fourth (high) quartile DRI scores based on a defined ...

Подробнее
02-01-2020 дата публикации

Multi-Parameter Diabetes Risk Evaluations

Номер: US20200005943A1
Принадлежит: LipoScience, Inc.

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. 1. A method of evaluating a subject's risk of developing type 2 diabetes and/or of having prediabetes , comprising:programmatically calculating a diabetes risk index score of a subject using at least one defined mathematical model of risk of developing type 2 diabetes that includes at least one lipoprotein component, at least one branched chain amino acid and at least one inflammatory biomarker obtained from at least one in vitro biosample of the subject.2. The method of claim 1 , further comprising programmatically defining at least two different mathematical models of risk of developing type 2 diabetes claim 1 , the at least two different mathematical models including one for subjects on a statin therapy that includes lipoprotein component that are statin insensitive and one for subjects not on a statin therapy.3. The method of claim 1 , further comprising pro grammatically defining at least two different mathematical models of risk of developing type 2 diabetes claim 1 , the at least two different mathematical models with different lipoprotein components including one for fasting biosamples claim 1 , and one for non-fasting biosamples.45-. (canceled)6. The method of claim 1 , wherein the at least one defined mathematical model of risk includes NMR derived measurements of a plurality of selected lipoprotein components of the at least one biosample of the subject claim 1 , and NMR measurements of at least one of GlycA and valine.7. The method of claim 1 , further comprising programmatically evaluating a fasting blood glucose measurement of the subject using at ...

Подробнее
18-03-2021 дата публикации

NMR Measurements of NMR Biomarker GlycA

Номер: US20210080452A1
Принадлежит: Liposcience Inc

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Подробнее
28-05-2015 дата публикации

Nmr quantification of tmao

Номер: US20150149094A1
Принадлежит: Liposcience Inc

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM.

Подробнее
28-05-2015 дата публикации

MULTI-PARAMETER DIABETES RISK EVALUATIONS

Номер: US20150149095A1
Принадлежит:

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. 1. A method of evaluating a subject's risk of developing type 2 diabetes , comprising:programmatically calculating a diabetes risk index of a subject using at least one defined mathematical model of risk of developing type 2 diabetes that includes a measurement of at least one lipoprotein component and at least one of a measurement of (i) GlycA or GlycB or (ii) at least one branched chain amino acid, obtained from at least one in vitro biosample of the subject.2. The method of claim 1 , wherein one or more of the at least one lipoprotein component forms a numerator claim 1 , denominator or multiplication factor of at least one interaction parameter.3. The method of claim 1 , wherein the defined mathematical model of risk comprises GlycA claim 1 , wherein the at least one lipoprotein component comprises an interaction parameter defined by the measurement of GlycA multiplied by a concentration of a defined subpopulation of high density lipoprotein (HDL) particles.4. The method of claim 1 , wherein the at least one lipoprotein component of the defined mathematical model of risk comprises a first interaction parameter of the measurement of GlycA multiplied by a concentration of a defined subpopulation of high density lipoprotein (HDL) particles and wherein the HDL subpopulation comprises only medium HDL particle subclasses with diameters between about 8.3 nm (average) to about 10.0 nm (average).56-. (canceled)7. The method of claim 1 , further comprising programmatically generating a report with a graph of risk of progression to type 2 diabetes in the future versus ranges of ...

Подробнее
12-11-2020 дата публикации

NMR Quantification of TMAO

Номер: US20200355634A1
Принадлежит: LipoScience, Inc.

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM. 1. A method of determining a measure of TMAO in in vitro biosamples , comprising:calibrating NMR measurements for trimethylamine-N-oxide (“TMAO”) by identifying a location of a reference peak and using a defined linear relationship between the location of the reference peak and a location of the calibration peak;generating a proton NMR spectrum for an in vitro biosample; andelectronically determining a level of TMAO in the in vitro biosample using a defined TMAO peak region having a single TMAO peak residing between about 3.2 and 3.4 ppm of the proton NMR spectrum,wherein the calibration peak is electronically identified in a defined calibration peak region in the NMR spectrum of the biosample.2. The method of claim 1 , further comprising:electronically calculating a distance between the reference and calibration peak regions; andelectronically determining a location of the TMAO peak for the defined TMAO peak region based on the calculated distance.3. (canceled)4. The method of claim 1 , wherein the biosample is a blood plasma or serum wherein the defined TMAO peak is at about 3.30 ppm.5. The method of claim 1 , further comprising:electronically identifying a defined calibration peak multiplet with peaks that can vary in distance apart from one another based on pH of the biosample;determining at least one distance between one or more of the peaks in the calibration peak multiplet; andelectronically determining a pH of the biosample based on the at least one determined distance;wherein the electronically determining the location of the TMAO peak for the defined TMAO peak region is carried ...

Подробнее
12-12-2013 дата публикации

Multi-parameter diabetes risk evaluations

Номер: CA2875201A1
Принадлежит: Liposcience Inc

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Подробнее
12-07-2022 дата публикации

Multi-parameter diabetes risk evaluations

Номер: CA2875201C
Принадлежит: Liposcience Inc

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Подробнее
10-10-2023 дата публикации

NMR quantification of TMAO

Номер: US11782002B2
Принадлежит: Liposcience Inc

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM.

Подробнее
15-04-2015 дата публикации

Nmr measurements of glyca

Номер: EP2859339A1
Принадлежит: Liposcience Inc

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of "GlycA" in arbitrary units or in defined units (e.g., µmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Подробнее
03-08-2016 дата публикации

Nmr measurements of glyca

Номер: EP2859339A4
Принадлежит: Liposcience Inc

Подробнее
23-06-2021 дата публикации

Nmr measurements of glyca

Номер: EP3839544A1
Принадлежит: Liposcience Inc

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of "GlycA" in arbitrary units or in defined units (e.g., µmοl/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Подробнее
19-04-2022 дата публикации

Nmr measurements of glyca

Номер: CA2874550C
Принадлежит: Liposcience Inc

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of "GlycA" in arbitrary units or in defined units (e.g., µmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Подробнее
30-12-2014 дата публикации

Nmr measurements of glyca

Номер: SG11201407803TA
Принадлежит: Liposcience Inc

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/184483 A1 (51) International Patent Classification: G01N24/08 (2006.01) G01N33/49 (2006.01) A61B 5/055 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/043343 30 May 2013 (30.05.2013) English (30) Priority Data: 61/657,315 8 June 2012 (08.06.2012) 61/711,471 9 October 2012 (09.10.2012) 61/739,305 19 December 2012 (19.12.2012) 13/830,199 14 March 2013 (14.03.2013) English US US us us (71) Applicant: LIPOSCIENCE, INC. [US/US]; 2500 Sumner Boulevard, Raleigh, North Carolina 27616 (US). (72) Inventors: OTVOS, James D.; 1117 Wellstone Circle, Apex, North Carolina 27502 (US). SHALAUROVA, Ir- ina Y.; 315 Ambermore Place, Cary, North Carolina 27519 (US). BENNETT, Dennis W.; 4242 North Morris Blvd., Shorewood, Wisconsin 53211 (US). WOLAK- DINSMORE, Justyna E.; 2808 Mebane Ln., Durham, North Carolina 27703 (US). (74) Agent: MYERS BIGEL SIBLEY & SAJOVEC, P.A.; P.O. Box 37428, Raleigh, North Carolina 27627 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA ...

Подробнее
12-12-2013 дата публикации

Nmr measurements of glyca

Номер: CA3146947A1
Принадлежит: Liposcience Inc

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of "GlycA" in arbitrary units or in defined units (e.g., mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Подробнее
21-03-2024 дата публикации

Multi-Parameter Diabetes Risk Evaluations

Номер: US20240096497A1
Принадлежит: Liposcience Inc

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Подробнее
08-05-2024 дата публикации

Multi-parameter diabetes risk evaluations

Номер: EP4365913A2
Принадлежит: Liposcience Inc

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Подробнее
07-03-2024 дата публикации

Methods and Systems for Measuring Citrate and Creatinine Levels by NMR Spectroscopy

Номер: US20240077439A1
Принадлежит: Laboratory Corp of America Holdings

Methods and systems for detecting a presence and a concentration of biomarkers relevant to kidney stone formation may be useful in determining a personalized therapeutic approach for a subject. Nuclear Magnetic Resonance (NMR) spectroscopy may be a valuable tool in detecting various biomarkers related to various disease states. A biosample obtained from a subject may be examined using NMR spectroscopy to determine the presence and the concentration of relevant biomarkers.

Подробнее
15-04-2015 дата публикации

Nmr quantification of tmao

Номер: EP2859338A1
Принадлежит: Liposcience Inc

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide ("TMAO"). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 µM or urine with a normal biologic range of between about 0-1000 µM.

Подробнее
18-04-2024 дата публикации

NMR Quantification of TMAO

Номер: US20240125719A1
Принадлежит: Liposcience Inc

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosample may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM.

Подробнее
07-03-2024 дата публикации

Methods and systems for measuring citrate and creatinine levels by nmr spectroscopy

Номер: WO2024050029A1

Methods and systems for detecting a presence and a concentration of biomarkers relevant to kidney stone formation may be useful in determining a personalized therapeutic approach for a subject. Nuclear Magnetic Resonance (NMR) spectroscopy may be a valuable tool in detecting various biomarkers related to various disease states. A biosample obtained from a subject may be examined using NMR spectroscopy to determine the presence and the concentration of relevant biomarkers.

Подробнее
07-08-2024 дата публикации

Multi-parameter diabetes risk evaluations

Номер: EP4365913A3
Принадлежит: Liposcience Inc

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Подробнее
02-10-2024 дата публикации

Nmr measurements of glyca for determining coronary heart disease risk

Номер: EP4439587A2
Принадлежит: Liposcience Inc

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of "GlycA" in arbitrary units or in defined units (e.g., µmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Подробнее